Navigation Links
Antibacterial Drugs Market (By Class and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
Date:8/6/2014

LONDON, Aug. 6, 2014 /PRNewswire/ -- LON-ReportbuyerReportbuyer.com has added a new market research report:

Antibacterial Drugs Market (By Class and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

http://www.reportbuyer.com/pharma_healthcare/therapeutic/antibacterial_drugs_market_by_class_pipeline_analysis_global_industry_analysis_size_share_growth_trends_forecast_2013_2019.html

Antibacterial Drugs Market (By Class - Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols, and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs, namely, aminoglycosides, B-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides and phenicols. The market for these classes has been extensively analyzed on the basis of the leading drug launch, expiry, efficacy, sales revenue and geographic presence. The market size and forecast in terms of USD million for each of these classes has been provided for the period 2011 to 2019, considering 2012 as the base year. The report on antibacterial drugs market also provides % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 to 2019.

Geographically, the antibacterial drugs market has been categorized into four regions namely, North America, Europe, Asia-Pacific, and Rest of the World (ROW). The market sizes and forecasts for each of these regions has been provided for the period 2011 to 2019 along with CAGR (%) for the forecast period 2013 to 2019. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the global antibacterial drugs market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis and Porter's five forces analysis for the antibacterial drugs market.

This report includes a chapter on competitive landscape which includes market share analysis of the leading players in the antibacterial drugs market, in terms of percentage share in the year 2012. A list of recommendations has also been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report also comprises a section on pipeline analysis for this market that includes sales forecast for various drugs currently under phase III clinical trials and expected to be launched during the forecast period.

The report also profiles major players of the antibacterial drugs market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Co., Forest Laboratories, Inc., GlaxoSmithKline plc, Merck & Co., Inc. and other significant players.

The global antibacterial drugs market is segmented as follows:

Antibacterial Drugs Market, by Class

Aminoglycosides
B-Lactams
Tetracyclines
Sulfonamides
Quinolones/Fluoroquinolones
Macrolides
Phenicols

Antibacterial Drugs Market, by Geography

North America
Europe
Asia-Pacific
Rest of the World (RoW)

Table of Content

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Sources
1.3.1.1 Secondary Research
1.3.1.2 Primary Research

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction to Antibacterial Drugs
3.2 Market Trends and Future Outlook
3.2.1 Impact of generics
3.3 Market Drivers
3.3.1 Global increasing prevalence of a large number of infectious diseases
3.3.2 Rising demand for effective and affordable antibacterial drugs from emerging economies
3.3.3 Aging population
3.4 Market Restraints
3.4.1 Weak pipeline of novel antibacterial drugs
3.4.2 Patent expirations
3.4.3 Rising number of generic drugs in various antibacterial drug classes

3.4.4 Increasing number of multi-drug resistant bacterial strains
3.5 Market Opportunities
3.5.1 Product differentiation through technological innovation, use of monoclonal antibodies (mAbs), combination products, new formulations and indications
3.5.2 Product development through partnerships
3.6 Porter's Five Forces Analysis for the Global Antibacterial Drugs Market
3.6.1 Bargaining power of suppliers
3.6.2 Bargaining power of buyers
3.6.3 Threat of substitutes
3.6.4 Threat of new entrants
3.6.5 Competitive rivalry
3.7 Market Attractiveness Analysis: Global Antibacterial Drugs Market, by Geography

Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million)
4.1 Overview
4.1.1 Global Antibacterial Drugs Market Revenue, by Class, 2011 – 2019 (USD Million)
4.1.2 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Class, 2012 & 2019 (Value %)
4.2 Aminoglycosides
4.2.1 Global Aminoglycosides Market Revenue, 2011 – 2019 (USD Million)
4.3 B-Lactams
4.3.1 Global B-Lactams Market Revenue, 2011 – 2019 (USD Million)
4.3.2 Penicillins
4.3.3 Carbapenems

4.3.4 Cephalosporins
4.4 Tetracyclines
4.4.1 Global Tetracyclines Market Revenue, 2011 – 2019 (USD Million)
4.5 Sulfonamides
4.5.1 Global Sulfonamides Market Revenue, 2011 – 2019 (USD Million)
4.6 Quinolones/Fluoroquinolones
4.6.1 Global Quinolones/Fluoroquinolones Market Revenue, 2011 – 2019 (USD Million)
4.7 Macrolides
4.7.1 Global Macrolides Market Revenue, 2011 – 2019 (USD Million)
4.8 Phenicols
4.8.1 Global Phenicols Market Revenue, 2011 – 2019 (USD Million)

Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million)
5.1 Overview
5.2 Delafloxacin (RX-3341)
5.2.1 Global Delafloxacin Market, 2015 – 2019 (USD Million)
5.3 Surotomycin (CB-315)
5.3.1 Global Surotomycin Market, 2016 – 2019 (USD Million)
5.4 Tedizolid (TR-701)
5.4.1 Global Tedizolid Market, 2015 – 2019 (USD Million)
5.5 Ceftolozane/Tazobactam
5.5.1 Global Ceftolozane/Tazobactam Market, 2015 – 2019 (USD Million)
5.6 Dalvance (dalbavancin)
5.6.1 Global Dalvance (dalbavancin) Market, 2015 – 2019 (USD Million)
5.7 Eravacycline (TP-434)
5.7.1 Global Eravacycline Market, 2016 – 2019 (USD Million)

5.8 Delamanid (OPC-67683)
5.8.1 Global Delamanid Market, 2017 – 2019 (USD Million)
5.9 CAZ AVI
5.9.1 Global CAZ AVI Market, 2015 – 2019 (USD Million)
5.10 Solithromycin (CEM-101)
5.10.1 Global Solithromycin Market, 2016 – 2019 (USD Million)
5.11 MK-3415A
5.11.1 Global MK-3415A Market, 2016 – 2019 (USD Million)
5.12 Oritavancin
5.12.1 Global Oritavancin Market, 2015 – 2019 (USD Million)

Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million)
6.1 Overview
6.1.1 Global Antibacterial Drugs Market Revenue, by Geography, 2011 – 2019 (USD Million)
6.1.2 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Geography, 2012 & 2019 (Value %)
6.2 North America
6.2.1 North America Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)
6.3 Europe
6.3.1 Europe Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)
6.4 Asia-Pacific
6.4.1 Asia-Pacific Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 RoW Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)

Chapter 7 Competitive Landscape
7.1 Market Share Analysis: Global Antibacterial Drugs Market (2012)

Chapter 8 Recommendations
8.1 Development of combination products
8.2 Generic pharmaceuticals: Targeting emerging markets such as India, China, Brazil, Mexico and South Africa
8.3 Strategic collaborations with small biotechnology and research companies

Chapter 9 Company Profiles
9.1 AstraZeneca plc
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies
9.1.5 Recent Developments
9.2 Bayer AG
9.2.1 Company Overview
9.2.2 Financial Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.2.5 Recent Developments
9.3 Bristol-Myers Squibb Company
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.3.5 Recent Developments
9.4 Eli Lilly and Company
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies
9.4.5 Recent Developments
9.5 Forest Laboratories, Inc.
9.5.1 Company Overview

9.5.2 Financial Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies
9.5.5 Recent Developments
9.6 GlaxoSmithKline plc
9.6.1 Company Overview
9.6.2 Financial Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies
9.6.5 Recent Developments
9.7 Johnson & Johnson

9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies
9.7.5 Recent Developments
9.8 Merck & Co., Inc.
9.8.1 Company Overview
9.8.2 Financial Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies
9.8.5 Recent Developments
9.9 Novartis AG
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies
9.9.5 Recent Developments
9.10 Pfizer, Inc.
9.10.1 Company Overview
9.10.2 Financial Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies
9.10.5 Recent Developments
9.11 Sanofi
9.11.1 Company Overview
9.11.2 Financial Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies
9.11.5 Recent Developments

List of Figures

FIG. 1 Antibacterial Drugs: Market Segmentation
FIG. 2 Global Antibacterial Drugs Market, by Class, 2012 (USD Million)
FIG. 3 Porter's Five Forces Analysis: Global Antibacterial Drugs Market
FIG. 4 Market Attractiveness Analysis: Global Antibacterial Drugs Market, by Geography (2012)
FIG. 5 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Class, 2012 & 2019 (Value %)
FIG. 6 Global Aminoglycosides Market Revenue, 2011 – 2019 (USD Million)
FIG. 7 Global ?-Lactams Market Revenue, 2011 – 2019 (USD Million)
FIG. 8 Global Tetracyclines Market Revenue, 2011 – 2019 (USD Million)
FIG. 9 Global Sulfonamides Market Revenue, 2011 – 2019 (USD Million)
FIG. 10 Global Quinolones/Fluoroquinolones Market Revenue, 2011 – 2019 (USD Million)
FIG. 11 Global Macrolides Market Revenue, 2011 – 2019 (USD Million)
FIG. 12 Global Phenicols Market Revenue, 2011 – 2019 (USD Million)
FIG. 13 Global Delafloxacin Market, 2015 – 2019 (USD Million)
FIG. 14 Global Surotomycin Market, 2016 – 2019 (USD Million)
FIG. 15 Global Tedizolid Market, 2015 – 2019 (USD Million)
FIG. 16 Global Ceftolozane/Tazobactam Market, 2015 – 2019 (USD Million)

FIG. 17 Global Dalvance (Dalbavancin) Market, 2015 – 2019 (USD Million)
FIG. 18 Global Eravacycline Market, 2016 – 2019 (USD Million)
FIG. 19 Global Delamanid Market, 2017 – 2019 (USD Million)
FIG. 20 Global CAZ AVI Market, 2015 – 2019 (USD Million)
FIG. 21 Global Solithromycin Market, 2016 – 2019 (USD Million)
FIG. 22 Global MK-3415A Market, 2016 – 2019 (USD Million)
FIG. 23 Global Oritavancin Market, 2015 – 2019 (USD Million)
FIG. 24 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Geography, 2012 & 2019 (Value %)
FIG. 25 North America Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 26 Europe Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 27 Asia-Pacific Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 28 RoW Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 29 Market Share by Key Players: Global Antibacterial Drugs Market, 2012 (%)
FIG. 30 Annual Revenue: AstraZeneca plc, 2010 – 2012 (USD Million)
FIG. 31 Annual Revenue: Bayer AG, 2010 – 2012 (USD Million)
FIG. 32 Annual Revenue: Bristol-Myers Squibb Company 2010 – 2012 (USD Million)
FIG. 33 Annual Revenue: Eli Lilly and Company 2010 – 2012 (USD Million)
FIG. 34 Annual Revenue: Forest Laboratories, Inc., 2010 – 2012 (USD Million)
FIG. 35 Annual Revenue: GlaxoSmithKline plc 2010 – 2012 (USD Million)
FIG. 36 Annual Revenue: Johnson & Johnson 2010 – 2012 (USD Million)
FIG. 37 Annual Revenue: Merck & Co., Inc. 2010 – 2012 (USD Million)
FIG. 38 Annual Revenue: Novartis AG 2010 – 2012 (USD Million)
FIG. 39 Annual Revenue: Pfizer, Inc. 2010 – 2012 (USD Million)
FIG. 40 Annual Revenue: Sanofi, 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Antibacterial Drugs Market
TABLE 2 Global Antibacterial Drugs Market Revenue, by Class, 2011 – 2019 (USD Million)
TABLE 3 Global Antibacterial Drugs Market Revenue, by Geography, 2011 – 2019 (USD Million)


Read the full report:
Antibacterial Drugs Market (By Class and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

http://www.reportbuyer.com/pharma_healthcare/therapeutic/antibacterial_drugs_market_by_class_pipeline_analysis_global_industry_analysis_size_share_growth_trends_forecast_2013_2019.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


'/>"/>
SOURCE ReportBuyer
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
2. Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022
3. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
4. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
5. Ophthalmic Drugs: World Market Prospects 2012-2022
6. Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
7. INTAC™ Technology Combats Misuse of Extended Release Drugs
8. Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise
9. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
10. Bilcare and CSIR to Partner on nonClonableID Technology for Authentication of Drugs
11. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 Laboratory glassware ... in laboratories. These may range from microscope slides to ... is made from borosilicate glass because of its low ... the other hand, started gaining popularity over the past ... to replace glass with plastic in several applications due ...
(Date:2/11/2016)... -- Governor Andrew M. Cuomo today announced a major expansion ... Western New York . This announcement, made ... includes a major expansion of Athenex,s North American headquarters ... , as well as the creation of a state-of-the-art, ... . The combined projects are expected to yield ...
(Date:2/11/2016)... 11, 2016  NOIT™ Research LLC, a private, leading-edge ... Change" campaign to assist needy families in obtaining one ... sold between February 10, 2016 and March 31, 2016, ... family. The NOIT is an auditory stimulus that plays ... language skills. Beth Shier , NOIT ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Clinical Data Management Solution Providers list for its expertise in eClinical Solutions. DDi ... expertise to serve the technology needs of global clients. DDi provides smarter technology ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, ... demanding job, and no time to decompress, Rabinowitz found herself drawn to a casual ... for its impact on her life, implementing a 20-minute-per-day meditation practice with her team. ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
Breaking Medicine News(10 mins):